2020 POSTERS

  • Complementary and Alternative Therapies (CAM)
  • Case Reports / Case Series (CRS)
  • Disease-modifying Therapy Part 1 (DXT)
  • Disease-modifying Therapy Part 2 (DXT)
  • Epidemiology and Genetics (EPI)
  • Family and Caregivers (FAM)
  • Internet and Information Services (IIS)
  • Imaging (IMG)
  • Multidisciplinary Care (MDC)
  • Methods of Care (MOC)
  • Neuroimmunology and Disease Models (NDM)
  • Non-imaging Biomarkers (NIB)
  • Neurophysiology; Neuropsychology and Neuropsychiatry (NNN)
  • Programs (PGM)
  • Psychosocial Factors (PSF)
  • Quality of Life and Outcomes (QOL)
  • Rehabilitation (REH)
  • Relapse Therapy (RTH)
  • Self-care (SEL)
  • Symptom Management (SXM)
  • Late-Breaking Abstracts
  • Whitaker Track

COMPLEMENTARY AND ALTERNATIVE THERAPIES

ID: CAM01
Multiple Sclerosis Imbalance: Visual Rehabilitation
Marcia Baptista Dias,1 Alice Estevo Dias2
1Rehabilitation and 2Scientific Research, Brazilian Association of Multiple Sclerosis, Sao Paulo, Brazil
VIEW THE ABSTRACT
ID: CAM02
Acupuncture and Electromagnet
Alice Estevo Dias,1 Teresa Cristina Vieira2
1Scientific Research and 2Rehabilitation, Brazilian Association of Multiple Sclerosis, Sao Paulo, Brazil
VIEW THE ABSTRACT
ID: CAM03
The Effects of Reflexology in People with Multiple Sclerosis
Alice Estevo Dias,1 Evanda Soares Oliveira2
1Scientific Research and 2Rehabilitation, Brazilian Association of Multiple Sclerosis, Sao Paulo, Brazil
VIEW THE ABSTRACT
ID: CAM04
The Effects of CBD:THC Tincture Oil in Reducing Symptoms and Overall Symptom Management Medication Dosages, in Persons with Multiple Sclerosis
Aryn Sieber,1 Kristine Werner,2 Karen Carera,3 Ben Thrower,4 Jacqueline Rosenthal4
1CannaCauses Foundation, Los Angeles, CA; 2Smyrna, GA; 3Brookhaven, GA; 4Andrew C. Carlos MS Institute, Shepherd Center, Atlanta, GA
VIEW THE ABSTRACT

Time: 7:00 – 7:40 pm ET | Meeting Password: 3Mh55F

ID: CAM05
Challenges and Opportunities in Progressive Multiple Sclerosis Trials: Lessons from Lipoic Acid

Carin S. Waslo,1,2 M. Mateo Paz Soldan,3,4 Mark S. Freedman,5 Pavle Repovic,6 Andrew J. Solomon,7 John R. Rinker,8 Mitchell T. Wallin,9 Jodie K. Haselkorn,10 Rebecca I. Spain11
1Neurology, VA Portland Health Care System, Portland, OR; 2Neurology, Oregon Health & Science University, Portland, OR; 3Neurology, University of Utah, Salt Lake City, UT; 4Neurology, VA Salt Lake City HCS, Salt Lake City, UT; 5University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada; 6Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA; 7Neurological Sciences, University of Vermont College of Medicine, Burlington, VT; 8Neurology, University of Alabama at Birmingham,
Birmingham, AL; 9Washington, DC VAMC, MS Center of Excellence, Washington, DC; 10Department of Epidemiology, University of Washington, Seattle, WA; 11Oregon Health & Science University, Portland, OR

VIEW THE ABSTRACT
ID: CAM06
Exercise in Medicine: A Complementary Exercise Promotion Approach Within Comprehensive Multiple Sclerosis Care
Emma V. Richardson,1 Elizabeth Barstow,2 Matthew Fifolt,3 Robert W. Motl1
1Department of Physical Therapy, 2Department of Occupational Therapy, and 3Department of Health Care Organization & Policy, University of Alabama at Birmingham, Birmingham, AL
VIEW THE ABSTRACT
ID: CAM07
Changes in Dietary Habits of Individuals Living with Multiple Sclerosis Enrolled in a Day Wellness Program
Zoe Edwards,1 Brian Hutchinson,2 Tiffany Malone1
1Multiple Sclerosis Achievement Center, Dignity Health, Citrus Heights, CA; 2Multiple Sclerosis Achievement Center, Dignity Health, Sacramento, CA
VIEW THE ABSTRACT

CASE REPORT AND CASE SERIES

ID: CRS01
Seasonal Variation and Other Observations in Myelin Oligodendrocyte Glycoprotein (MOG) Antibody– Associated Disease

Allison N. Block, Ahmed Z. Obeidat
Neurology, Medical College of Wisconsin, Milwaukee, WI

VIEW THE ABSTRACT

Time: 7:30 – 8:10 pm ET

ID: CRS02
Multiple Surgeries and Misdiagnosis Before Multiple Sclerosis Diagnosis: A Case Report
Angel Lopez,1 Joanie Figueroa-Amaro,2 Astrid Diaz,1 Viviana Martinez,1 Ivonne Vicente,1 Angel Chinea1
1San Juan Multiple Sclerosis Center, Guaynabo, PR; 2Medicine, San Juan Bautista School of Medicine, Caguas, PR
VIEW THE ABSTRACT
ID: CRS03
Head Trauma as Onset for Multiple Sclerosis Diagnosis: A Case Report

Astrid Diaz, Viviana Martinez, Ivonne Vicente, Cristina M. Rubi, Angel Lopez, Angel Chinea
San Juan Multiple Sclerosis Center, Guaynabo, PR

VIEW THE ABSTRACT
ID: CRS04
Team Approach Yields Surprising Functional Progress and Quality-of-Life Changes in a Challenging Case of Neuromyelitis Optica
Clare T. Hartigan,1 Christopher Wells2
1Multiple Sclerosis Outpatient Rehabilitation, Shepherd Center, Atlanta, GA; 2Multiple Sclerosis Wellness Program, Shepherd Center, Atlanta, GA
VIEW THE ABSTRACT

Time: 7:00 – 7:40 pm ET | Meeting Password: 3Wgty4

ID: CRS05
Differential Diagnosis and Treatment of Tumefactive Demyelination in a Teenaged Girl
Gillian R. Paton, Sarah Hopkins
Division of Neurology, Multiple Sclerosis and Neuroinflammatory Disorders, Children’s Hospital of Philadelphia, Philadelphia, PA
VIEW THE ABSTRACT
ID: CRS06
A Long-Standing Case of Recurrent Transverse Myelitis Due to Myelin Oligodendrocyte Glycoprotein (MOG)–IgG Antibody Mimicking Multiple Sclerosis
Gina S. Perez, Peggy J. Wisdom, Nidhiben Anadani
Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
VIEW THE ABSTRACT

Time: 7:00 – 7:40 pm ET

ID: CRS07
Case Report of Severe Multiple Sclerosis Relapse Due to B-Cell Reconstitution Post Alemtuzumab
Jennifer Chester,1 Tyler Kaplan2
1Kansas City Multiple Sclerosis Center, College Park Specialty Center, Overland Park, KS; 2Neuro-immunology, Rush University Medical Center and University of Utah, Chicago, IL
VIEW THE ABSTRACT

Time: 7:30 – 8:10 pm ET | Meeting Password: 6Au0i6

ID: CRS08
Demographics, Clinical Characteristics, and Outcomes of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease Followed Up at Washington University in St. Louis
John R. Ciotti, Anne Cross, Salim Chahin
Washington University in St. Louis, St. Louis, MO
VIEW THE ABSTRACT
ID: CRS09
A Fatal Case of Alemtuzumab-Induced Immune Thrombocytopenic Purpura in a Patient with Relapsing Multiple Sclerosis
Leila Saadatpour, Rebecca Romero
Neurology, University of Texas Health Science Center at San Antonio, San Antonio, TX
VIEW THE ABSTRACT

Meeting Password: 0VuS52

ID: CRS10
Colitis Associated with Teriflunomide
Neda Zarghami Esfahani,1 Gloria von Geldern,1 Meghan C. Romba,1 Dhavan Parikh,2 Annette Wundes1
1Neurology, University of Washington, Seattle, WA; 2Gastroenterology, Everett Clinic, Everett, WA
VIEW THE ABSTRACT
ID: CRS11
Remarkable Recovery of Fulminant Multiple Sclerosis After Treatment Induction with Cyclophosphamide
Nicola Carlisle,1 Sam I. Hooshmand,1 Michelle Maynard,2 Ahmed Z. Obeidat3
1Neurology, Medical College of Wisconsin and Affiliated Hospitals, Milwaukee, WI; 2Neurosciences, Froedtert and the Medical College of Wisconsin, Milwaukee, WI; 3Neurology, Medical College of Wisconsin, Milwaukee, WI
VIEW THE ABSTRACT
ID: CRS12
Neurofibromatosis Type 1 and Multiple Sclerosis in the Same Patient
Sargon Bet-Shlimon, Annette Wundes, Gloria von Geldern
Neurology, University of Washington, Seattle, WA
VIEW THE ABSTRACT

Time: 7:45 pm – 8:30 pm ET | Meeting Password: SGpVdDlHQVEwNEFJT2FMeDl2OFVzUT09

ID: CRS13
Successful Use of Immunotherapy for Osmotic Demyelination Syndrome
Wijdan Rai,1 Stephen Kolb2
1Neurology, Ohio State University, Columbus, OH; 2Ohio State University, Columbus, OH
VIEW THE ABSTRACT

Time: 7:00 pm – 7:40 pm ET | Meeting Password: 298147

DISEASE MODIFYING THERAPIES PART 1

ID: DXT01
Maintenance of Working Status and Work Productivity in Persons with Multiple Sclerosis Treated with Dimethyl Fumarate: A 5-Year Analysis of the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry

Amber Salter,1 Samantha Lancia,1 Gary Cutter,2 Robert J. Fox,3 Ruth Ann Marrie,4 Jason P. Mendoza,5 James B. Lewin5
1Biostatistics, Washington University School in St. Louis, School of Medicine, St. Louis, MO; 2Biostatistics, University of Alabama at Birmingham, Birmingham, AL; 3Cleveland Clinic, Cleveland, OH; 4Health Sciences Centre Winnipeg, University of Manitoba, Winnipeg, MB, Canada; 5Biogen, Cambridge, MA

VIEW THE ABSTRACT
ID: DXT02
Early Effect of Ofatumumab on B-Cell Counts and Magnetic Resonance Imaging Activity in Relapsing Multiple Sclerosis Patients: Results from the APLIOS Study
Amit Bar-Or,1 Edward J. Fox,2 Alexandra Goodyear,3 Inga Ludwig,4 Morten Bagger,4 Dieter A. Haering,4 Harald Kropshofer,4 Martin Merschhemke,4 Heinz Wiendl5
1Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 2Central Texas Neurology Consultants and Dell Medical School, The University of Texas at Austin, Round Rock, TX; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ; 4Novartis Pharma AG, Basel, Switzerland; 5Department of Neurology, University of Münster, Münster, Germany
VIEW THE ABSTRACT
ID: DXT03
Analyses of the Effect of Disease Duration on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the EXPAND Study

Amit Bar-Or,1 Stanley L. Cohan,2 Patricia K. Coyle,3 Fred D. Lublin,4 Xiangyi Meng,5 Wendy Su,5 Bruce A.C. Cree,6
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 2Providence Multiple Sclerosis Center, Providence Brain Institute, Portland, OR; 3Stony Brook University, Stony Brook, NY; 4Icahn School of Medicine at Mount Sinai, New York, NY; 5Novartis Pharmaceuticals Corporation, East Hanover, NJ; 6Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA

VIEW THE ABSTRACT
ID: DXT04
Siponimod First-Dose Effects in Patients with Secondary Progressive Multiple Sclerosis Receiving Concomitant Selective Serotonin Reuptake Inhibitor Therapy

Amit Bar-Or,1 Bruce A.C. Cree,2 Le H. Hua,3 Amos Katz,4 Derrick Robertson,5 Brandon Brown,6 Desiree Dunlop,6 Xiangyi Meng,6 Wendy Su6
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 2Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA; 3Lou Ruvo Center for Brain Health, Las Vegas, NV; 4Linda Cardinale MS Center, Freehold, NJ; 5University of South Florida, Multiple Sclerosis Center, Tampa, FL; 6Novartis Pharmaceuticals Corporation, East Hanover, NJ

VIEW THE ABSTRACT
ID: DXT05
Efficacy of Diroximel Fumarate in Highly Active Relapsing-Remitting Multiple Sclerosis: Interim Results from the Phase 3 EVOLVE-MS-1 Study

Annette Wundes,1 Enrique Alvarez,2 Mark S. Freedman,3 Oksana Mokliatchouk,4 Hailu Chen,4 Shivani Kapadia,4 Jordan Messer,4 Robert T. Naismith5
1Department of Neurology, University of Washington Medical Center, Seattle, WA; 2Department of Neurology, University of Colorado School of Medicine, Aurora, CO; 3University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada; 4Biogen, Cambridge, MA; 5Washington University School of Medicine, St. Louis, MO

VIEW THE ABSTRACT
ID: DXT06
Real-World Effectiveness of Peginterferon Beta1a Versus Interferon Beta-1a and Glatiramer Acetate in US Multiple Sclerosis Patients
Anthony T. Reder,1 Nancy Arndt,1 Caroline Geremakis,2 Jason P. Mendoza,2 Ray Su,2 Charles Makin,2 Megan C. Vignos,2 Robin L. Avila2
1University of Chicago Neurology, Chicago, IL; 2Biogen, Cambridge, MA
VIEW THE ABSTRACT
ID: DXT07
Injection Site Reactions and Risk of Discontinuation Among New and Experienced Peginterferon Beta-1a Users in the Plegridy Observational Program
Ayo Adeyemi,1 Nicole Tsao,1 Arman Altincatal,1 Maria L. Naylor,1 Marco Salvetti,2 Sibyl Wray,3 Gereon Nelles,4 Charles Makin1
1Biogen, Cambridge, MA; 2Sapienza University, S. Andrea Hospital, Rome, Italy; 3Hope Neurology, Knoxville, TN; 4Neurology, NeuroMed Campus Hohenlind, Cologne, Germany
VIEW THE ABSTRACT
ID: DXT08
Post Hoc Analysis of Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis Diagnosed Within 3 or 4 Years Prior to the CLARITY Study

Barry Singer,1 Gavin Giovannoni,2 Nicola De Stefano,3 Matt Mandel,4 Yann Hyvert,5 Julie Aldridge,4 Andrew Galazka,6 Caroline Lemieux,7 Mark S. Freedman8
1Missouri Baptist Medical Center, St Louis, MO; 2Blizard Institute of Cell and Molecular Science, London, United Kingdom; 3University of Siena, Siena, Italy; 4EMD Serono Inc, Billerica, MA; 5Merck KGaA, Darmstadt, Germany; 6Merck, Aubonne, Switzerland; 7EMD Serono Inc., Mississauga, ON, Canada; 8University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada

VIEW THE ABSTRACT
ID: DXT09
Exploration of Factors Which Influence Treatment Decisions of Patients with Multiple Sclerosis
Belinda Bardsley,1 John Haynes,2 Edith Cinc,1 Elise Heriot,1 K.-J. Lazarus,1 Melanie McMurtrie,1 Richard A.L. Macdonell3
1Neurology, Austin Health, Heidelberg, VIC, Australia; 2Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Parkville, VIC, Australia; 3Austin Health and Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia
VIEW THE ABSTRACT
ID: DXT10
Siponimod Affects Disability Progression in Patients with Secondary Progressive Multiple Sclerosis Independent of Relapse Activity: Results from the Phase 3 EXPAND Study

Bruce A.C. Cree,1 Robert J. Fox,2 Gavin Giovannoni,3 Patrick Vermersch,4 Amit Bar-Or,5 Ralf Gold,6 Nicolas Rouyrre,7 Goeril Karlsson,7 Frank Dahlke,7 Ludwig Kappos8
1Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA; 2Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH; 3Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom; 4Department of Neurology, University of Lille, CHU Lille, Lille, France; 5Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 6Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany; 7Novartis Pharma AG, Basel, Switzerland; 8Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Basel, Switzerland

VIEW THE ABSTRACT
ID: DXT11
The Implications of Suboptimal Treatment Outcomes with Disease-Modifying Drugs in Employees with Multiple Sclerosis

Carrie M. Hersh,1 Richard A. Brook,2 Ian A. Beren,3 Nicholas J. Rohrbacker,3 Lori Lebson,4 Christian Henke,5 Amy L. Phillips6
1Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV; 2Better Health Worldwide, Inc, Newfoundland, NJ; 3The HCMS Group, LLC, Pittsburgh, PA; 4EMD Serono, Inc, Rockland, MA; 5Merck KGaA, Darmstadt, Germany; 6Health Economics & Outcomes Research, EMD Serono, Inc, Rockland, MA

VIEW THE ABSTRACT
ID: DXT12
Real-World Effectiveness of Peginterferon Beta- 1a Versus Teriflunomide in US Multiple Sclerosis Patients
Cortnee Roman,1 Caroline Geremakis,2 Jason P. Mendoza,2 Ray Su,2 Charles Makin,2 Megan C. Vignos,2 Robin L. Avila2
1Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, UT; 2Biogen, Cambridge, MA
VIEW THE ABSTRACT
ID: DXT13
Disease-Modifying Therapies: How Confident Are We That We Understand Their Risk?
Cortnee Roman,1 Christen Kutz,2 Timothy West1
1Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, UT; 2Colorado Springs Neurological Associates, Colorado Springs, CO
VIEW THE ABSTRACT
ID: DXT14
Long-Term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder
Dean Wingerchuk,1 Sean J. Pittock,2 Achim Berthele,3 Kazuo Fujihara,4,5,6 Ho Jin Kim,7 Michael Levy,8,9 Jacqueline Palace,10 Ichiro Nakashima,4,11 Murat Terzi,12 Natalia Totolyan,13 Shanthi Viswanathan,14 Kai-Chen Wang,15,16 Kerstin Allen,17 Kenji P. Fujita,17 Marcus Yountz,17 Roisin Armstrong17
1Mayo Clinic, Scottsdale, AZ; 2Mayo Clinic, Rochester, MN; 3Technical University of Munich, Munich, Germany; 4Tohoku University, Sendai, Japan; 5Fukushima Medical University, Fukushima City, Japan; 6Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan; 7National Cancer Center, Goyang, Korea, Republic of (South); 8Massachusetts General Hospital and Harvard Medical School, Boston, MA; 9Johns Hopkins University, Baltimore, MD; 10John Radcliffe Hospital, Oxford, United Kingdom; 11Tohoku Medical and Pharmaceutical University, Sendai, Japan; 12Ondokuz Mayis University, Samsun, Turkey; 13First Pavlov State Medical University of St Petersburg, St Petersburg, Russian Federation; 14Kuala Lumpur Hospital, Kuala Lumpur, Malaysia; 15Cheng-Hsin General Hospital, Taipei, Taiwan; 16National Yang Ming University, Taipei, Taiwan; 17Alexion Pharmaceuticals, Boston, MA
VIEW THE ABSTRACT
ID: DXT15
Inebilizumab Reduces Neuromyelitis Optica Spectrum Disorder Disability Worsening: Outcomes and Long-Term Follow-up Data from the N-MOmentum Trial
Dean Wingerchuk,1 Romain Marignier,2 Jeffrey L. Bennett,3 Ho Jin Kim,4 Brian Weinshenker,5 Sean J. Pittock,6 Kazuo Fujihara,7 Friedemann Paul,8 Gary Cutter,9 Ari Green,10 Orhan Aktas,11 Hans-Peter Hartung,12 Fred D. Lublin,13 Maureen A. Mealy,14 Jorn Drappa,14 Gerard Barron,14 Soraya Madani,14 Dewei She,14 Daniel Cimbora,14 William Rees,14 John N. Ratchford,14 Eliezer Katz,14 Bruce A.C. Cree15
1Mayo Clinic, Scottsdale, AZ; 2Lyon University Hospital, Lyon, France; 3School of Medicine, University of Colorado, Aurora, CO; 4Research Institute and Hospital of National Cancer Center, Goyang, Korea, Republic of (South); 5Neurology, Mayo Clinic, Rochester, MN; 6Mayo Clinic, Rochester, MN; 7Department of Multiple Sclerosis Therapeutics, Southern Tohoku Research Institute for Neuroscience (STRINS), Koriyama, Japan; 8Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charite – Universitatsmedizin Berlin, Berlin, Germany; 9Biostatistics, University of Alabama at Birmingham, Birmingham, AL; 10Department of Neurology and Department of Ophthalmology, UCSF Weill Institute for Neurosciences, San Francisco, CA; 11Medical Faculty, Heinrich-Heine-University, Dusseldorf, Germany; 12Department of Neurology, UKD, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany; 13Icahn School of Medicine at Mount Sinai, New York, NY; 14Viela Bio, Gaithersburg, MD; 15Department of Neurology and Department of Ophthalmology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA
VIEW THE ABSTRACT
ID: DXT16
Effectiveness of Delayed-Release Dimethyl Fumarate Relative to Duration of Prior Glatiramer Acetate in Patients Enrolled in the RESPOND Study
Derrick Robertson,1 Pavle Repovic,2 Stanley L. Cohan,3 Yang Mao-Draayer,4 Ray Su,5 James B. Lewin,5 Jenna Borowski6
1USF Multiple Sclerosis Center, Tampa, FL; 2Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA; 3Providence Multiple Sclerosis Center, Providence Brain Institute, Portland, OR; 4University of Michigan Medical School, Ann Arbor, MI; 5Biogen, Cambridge, MA; 6Biogen, Weston, MA
VIEW THE ABSTRACT
ID: DXT17
Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis
Edward J. Fox,1 Sibyl Wray,2 Richard Shubin,3 Amy Lovett-Racke,4 Deren Huang,5 Ann D. Bass,6 Michael S. Weiss,7 Sean Power,7 Jenna Bosco,7 Koby Mok7
1Central Texas Neurology Consultants and Dell Medical School, The University of Texas at Austin, Round Rock, TX; 2Hope Neurology, Knoxville, TN; 3Arcadia Neurology Center, Arcadia, CA; 4Ohio State University, Columbus, OH; 5Mount Carmel Neurology, Westerville, OH; 6Neurology Center of San Antonio, San Antonio, TX; 7TG Therapeutics, New York, NY
VIEW THE ABSTRACT
ID: DXT18
Adherence and Compliance with Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis
Edward Fox,1 Lori Mayer,2 Angela Aungst,3 Alexandra Goodyear,4 Cecile Kerloeguen,5 Linda Mancione,4 Nicola Rennie,5 Dee Stoneman,5 Martin Zalesak,5 Marina Ziehn,4 Derrick Robertson,6 Jeffrey A. Cohen7
1Central Texas Neurology Consultants, Multiple Sclerosis Clinic of Central Texas, Round Rock, TX; 2MS Clinic of Central Texas, Central Texas Neurology Consultants, Round Rock, TX; 3Multiple Sclerosis Division Department of Neurology University of South Florida, Florida, FL; 4Novartis Pharmaceuticals Corporation, East Hanover, NJ; 5Novartis Pharma AG, Basel, Switzerland; 6College of Medicine, Neurology, University of South Florida, Tampa, FL; 7Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH
VIEW THE ABSTRACT
ID: DXT20
Glatiramer Acetate (GA) Produced by Mapi Pharma Is Equivalent to Commercially Available GA Preparations
Susanna Tchilibon, Nadav Bleich Kimelman, Shai Rubnov, Laura Popper, Uri Danon, Ehud Marom
Mapi Pharma Ltd, Ness Ziona, Israel
VIEW THE ABSTRACT
ID: DXT22
Characterization of Incidence and Time-toRecovery from Grade 3/4 Lymphopenia Lasting ≥6 Months in Patients with Multiple Sclerosis Treated with Cladribine Tablets
Gabriel Pardo,1 Kottil Rammohan,2 Thomas P. Leist,3 Julie Aldridge,4 Ciara Rossier,5 Axel Nolting,6 Matt Mandel,4 Andrew Galazka,5 Daniel Jones,7 Gavin Giovannoni8
1Oklahoma Medical Research Foundation, Oklahoma City, OK; 2Department of Neurology, Multiple Sclerosis Center, University of Miami, Miami, FL; 3Jefferson University Hospital, Philadelphia, PA; 4EMD Serono Inc, Billerica, MA; 5Merck, Aubonne, Switzerland; 6Merck KGaA, Darmstadt, Germany; 7EMD Serono Inc, Rockland, MA; 8Blizard Institute of Cell and Molecular Science, London, United Kingdom
VIEW THE ABSTRACT
ID: DXT23
Disease-Modifying Therapy Landscape: An Evaluation of Cost and Care
Gail Bridges,1 Douglas Mager,2 Mary Dorholt,2 Rochelle Henderson2
1Accredo, Memphis, TN; 2Express Scripts Inc, St. Louis, MO
VIEW THE ABSTRACT
ID: DXT24
Two Expanded Disability Status Scale Subscales Evaluated in Patients with Relapsing-Remitting or Secondary Progressive Multiple Sclerosis
Gary Cutter,1 Xiangyi Meng,2 Jamie L. Weiss,2 Ralph H.B. Benedict,3 Stanley L. Cohan,4 Bruce A.C. Cree,5 Wendy Su,2 Florian P. Thomas6,7
1School of Public Health, University of Alabama, Birmingham, AL; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ; 3University at Buffalo, State University of New York, Buffalo, NY; 4Providence Multiple Sclerosis Center, Providence Brain Institute, Portland, OR; 5Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA; 6Hackensack Meridian School of Medicine, Nutley, NJ; 7Department of Neurology, Multiple Sclerosis Center, Hackensack University Medical Center, Hackensack, NJ
VIEW THE ABSTRACT
ID: DXT26
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies
Gavin Giovannoni,1 Giancarlo Comi,2 Kottil Rammohan,3 Peter Rieckmann,4 Patrick Vermersch,5 Fernando Dangond,6 Birgit Keller,7 Dominic Jack7
1Queen Mary University of London, London, United Kingdom; 2Department of Neurology and Institute of Experimental Neurology, Universita Vita-Salute San Raffaele, Milan, Italy; 3Department of Neurology, Multiple Sclerosis Center, University of Miami, Miami, FL; 4Department of Neurology, Medical Park Loipl, and University of Erlangen, Erlangen, Germany; 5University of Lille, Lille, France; 6EMD Serono Inc, Billerica, MA; 7Merck KGaA, Darmstadt, Germany
VIEW THE ABSTRACT
ID: DXT27
Integrated Lymphopenia Analysis in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets
Gavin Giovannoni,1 Patricia K. Coyle,2 Patrick Vermersch,3 Bryan Walker,4 Julie Aldridge,5 Axel Nolting,6 Sana Syed,5 Andrew Galazka,7 Daniel Jones,8 Thomas P. Leist9
1Queen Mary University of London, London, United Kingdom; 2Stony Brook University, Stony Brook, NY; 3University of Lille, Lille, France; 4Neurological Department, Duke University School of Medicine, Durham, NC; 5EMD Serono Inc, Billerica, MA; 6Merck KGaA, Darmstadt, Germany; 7Merck, Aubonne, Switzerland; 8EMD Serono Inc, Rockland, MA; 9Jefferson University Hospital, Philadelphia, PA
VIEW THE ABSTRACT
ID: DXT28
Effectiveness of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis with Baseline Expanded Disability Status Scale Score ≥3.5 or ≤3.0 in CLARITY
Giancarlo Comi,1 Gabriel Pardo,2 Fernando Dangond,3 Julie Aldridge,3 Caroline Lemieux,4 Kottil Rammohan5
1Department of Neurology and Institute of Experimental Neurology, Universita Vita-Salute San Raffaele, Milan, Italy; 2Oklahoma Medical Research Foundation, Oklahoma City, OK; 3EMD Serono Inc, Billerica, MA; 4EMD Serono Inc, Mississauga, ON, Canada; 5Department of Neurology, Multiple Sclerosis Center, University of Miami, Miami, FL
VIEW THE ABSTRACT
ID: DXT29
ACAPELLA: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive Multiple Sclerosis, Year 3 Data
Hannah M Geils, India C. Stribling, Joshua D. Katz, Ellen S. Lathi
The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA
VIEW THE ABSTRACT
ID: DXT30
ACAPELLA: Hypogammaglobulinemia and JC Virus Status in Ocrelizumab-Treated Patients, Year 2 Data
Hannah M. Geils, India C. Stribling, Joshua D. Katz, Ellen S. Lathi
The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA
VIEW THE ABSTRACT
ID: DXT31
Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Neuromyelitis Optica Spectrum Disorder: Phase 3 PREVENT Study
Ho Jin Kim,1 Sean J. Pittock,2 Achim Berthele,3 Kazuo Fujihara,4,5,6 Michael Levy,7,8 Jacqueline Palace,9 Ichiro Nakashima,5,10 Murat Terzi,11 Natalia Totolyan,12 Shanthi Viswanathan,13 Kai-Chen Wang,14,15 Amy Pace,16 Kenji P. Fujita,16 Marcus Yountz,16 Roisin Armstrong,16 Dean Wingerchuk17
1National Cancer Center, Goyang, Korea, Republic of (South); 2Mayo Clinic, Rochester, MN; 3Technical University of Munich, Munich, Germany; 4Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan; 5Tohoku University, Sendai, Japan; 6Fukushima Medical University, Fukushima City, Japan; 7Massachusetts General Hospital and Harvard Medical School, Boston, MA; 8Johns Hopkins University, Baltimore, MD; 9John Radcliffe Hospital, Oxford, United Kingdom; 10Tohoku Medical and Pharmaceutical University, Sendai, Japan; 11Ondokuz Mayis University, Samsun, Turkey; 12First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation; 13Kuala Lumpur Hospital, Kuala Lumpur, Malaysia; 14National Yang Ming University, Taipei, Taiwan; 15Cheng-Hsin General Hospital, Taipei, Taiwan; 16Alexion Pharmaceuticals, Boston, MA; 17Mayo Clinic, Scottsdale, AZ
VIEW THE ABSTRACT
ID: DXT33
ACAPELLA: B-Cell Reconstitution in OcrelizumabTreated Patients
India C. Stribling, Hannah M. Geils, Joshua D. Katz, Ellen S. Lathi
The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA
VIEW THE ABSTRACT
ID: DXT34
Revealing the Immune Cell Subtype Reconstitution Profile in Cladribine-Treated Patients at the 96-Week Timepoint (CLARITY) Using Deconvolution Algorithms

Irina Kalatskaya,1 Gavin Giovannoni,2,3 Thomas P. Leist,4 Per Soelberg-Sorensen,5 Ursula Boschert,6 Julie DeMartino,1 Alex Rolfe1
1EMD Serono, Inc, Billerica, MA; 2Blizard Institute of Cell and Molecular Science, London, United Kingdom; 3Queen Mary University of London, London, United Kingdom; 4Jefferson University Hospital, Philadelphia, PA; 5Department of Neurology, Danish MS Center, University of Copenhagen, Copenhagen, Denmark; 6Merck Serono S.A., Eysins, Switzerland

VIEW THE ABSTRACT
ID: DXT35
Real-World Experience with Ocrelizumab: A Safety Analysis
Jamie Bolling,1 Ryan McNiff,2 Aaron Carlson,1 Carlos Vervloet Sollero,1 Tirisham V. Gyang1
1Neurology, University of Florida, Gainesville, FL; 2UF Health, University of Florida, Gainesville, FL
VIEW THE ABSTRACT
ID: DXT36
Effect of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, on Immune Cell and Immunoglobulin Levels over 48 Weeks in a Phase 2 Study in Relapsing Multiple Sclerosis
Xavier Montalban,1,2 Jamie Shaw,3 Sana Syed,3 Fernando Dangond,3 Emily C. Martin,3 Roland Grenningloh,3 Martin S. Weber,4 on behalf of the Evobrutinib Phase 2 Study Group 1Vall d’Hebron University Hospital, Barcelona, Spain; 2St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada; 3EMD Serono Research & Development Institute, Inc (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA; 4Institute of Neuropathology and Department of Neurology, University Medical Center, Gottingen, Germany
VIEW THE ABSTRACT
ID: DXT37
Effect of Teriflunomide on Brain Volume Loss in Patients with Relapsing Multiple Sclerosis of Differing Ages in TEMSO
Jiwon Oh,1 Jens Wuerfel,2 Bhupendra O. Khatri,3 Aaron E. Miller,4 Jihad Said Inshasi,5 Albert Saiz,6 Alex L. Lublin,7 Elizabeth M. Poole,7 Till Sprenger8,9 1University of Toronto, Toronto, ON, Canada; 2Medical Imaging Analysis Center (MIAC AG) and Department of Biomedical Engineering, University of Basel, Basel, Switzerland; 3Center for Neurological Disorders at Wheaton Franciscan Healthcare, Milwaukee, WI; 4Icahn School of Medicine at Mount Sinai, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, New York, NY; 5Dubai Medical College, Dubai, United Arab Emirates; 6Department of Neurology, Hospital Clinic and Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; 7Sanofi, Cambridge, MA; 8DKD Helios Klinik Wiesbaden, Wiesbaden, Germany; 9University Hospital Basel, Basel, Switzerland
VIEW THE ABSTRACT
ID: DXT38
Effects of Ozanimod on Information Processing Speed: Findings from the Phase 3 SUNBEAM and DAYBREAK Extension Trials
John DeLuca,1 Jeffrey A. Cohen,2 Bruce A.C. Cree,3 Hongjuan Liu,4 James K. Sheffield,4 Diego Silva,4 Giancarlo Comi,5 Ludwig Kappos6
1Kessler Foundation, West Orange, New Jersey and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers – New Jersey Medical School, Newark, NJ; 2Mellen Center, Cleveland Clinic, Cleveland, OH; 3Department of Neurology and Department of Ophthalmology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA; 4Bristol-Myers Squibb, Summit, NJ; 5Department of Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; 6Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital of Basel, Basel, Switzerland
VIEW THE ABSTRACT

DISEASE MODIFYING THERAPIES PART 2

ID: DXT40
Effect of the S1P1/5 Receptor Modulator Ozanimod on Cognitive Processing Speed in Subjects with Relapsing Multiple Sclerosis: Design of the ENLIGHTEN Study
Jon V. Riolo,1 Ling Yang,1 Thomas Rano,1 Robert Zivadinov,2 Lauren B. Krupp,3 Jonathan Calkwood,4 Olaf Stuve,5 Robert T. Naismith,6 Diego Silva,1 John DeLuca7
1Bristol-Myers Squibb, Summit, NJ; 2Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY; 3Stony Brook Technology Park, East Setauket, NY; 4Minneapolis Clinic of Neurology, Golden Valley, MN; 5UT Southwestern Medical Center, Dallas, TX; 6Washington University School of Medicine, St. Louis, MO; 7Kessler Foundation, West Orange, New Jersey and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers – New Jersey Medical School, Newark, NJ
VIEW THE ABSTRACT
ID: DXT41
Eculizumab Benefits a Broad Range of Patients with Aquaporin-4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder: The Phase 3 PREVENT Study
Kazuo Fujihara,1,2,3 Achim Berthele,4 Ho Jin Kim,5 Michael Levy,6,7 Ichiro Nakashima,2,8 Celia Oreja-Guevara,9 Jacqueline Palace,10 Sean J. Pittock,11 Murat Terzi,12 Natalia Totolyan,13 Shanthi Viswanathan,14 Kai-Chen Wang,15,16 Amy Pace,17 Marcus Yountz,17 Larisa Miller,17 Imran Tanvir,17 Roisin Armstrong,17 Dean Wingerchuk18
1Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan; 2Tohoku University, Sendai, Japan; 3Fukushima Medical University, Fukushima City, Japan; 4Technical University of Munich, Munich, Germany; 5National Cancer Center, Goyang, Korea, Republic of (South); 6Massachusetts General Hospital and Harvard Medical School, Boston, MA; 7Johns Hopkins University, Baltimore, MD; 8Tohoku Medical and Pharmaceutical University, Sendai, Japan; 9Hospital Universitario Clinico San Carlos, Madrid, Spain; 10John Radcliffe Hospital, Oxford, United Kingdom; 11Mayo Clinic, Rochester, MN; 12Ondokuz Mayis University, Samsun, Turkey; 13First Pavlov State Medical University of St Petersburg, St Petersburg, Russian Federation; 14Kuala Lumpur Hospital, Kuala Lumpur, Malaysia; 15National Yang Ming University, Taipei, Taiwan; 16Cheng-Hsin General Hospital, Taipei, Taiwan; 17Alexion Pharmaceuticals, Boston, MA; 18Mayo Clinic, Scottsdale, AZ
VIEW THE ABSTRACT
ID: DXT42
Rationale and Design of CLASSIC-MS Study Evaluating Long-Term Efficacy for Patients with Multiple Sclerosis Treated with Cladribine Tablets

Alexey Boyko,1 Jorge Correale,2 Gilles Edan,3 Mark S. Freedman,4 Gavin Giovannoni,5 Xavier Montalban,6,7 Kottil Rammohan,8 Thomas P. Leist,9 Dusan Stefoski,10 Bassem Yamout,11 Belen Garcia-Alonso,12 Aida Aydemir,13 Elisabetta Verdun di Cantogno,12 CLASSIC-MS Study Group
1Pirogov Russian National Research Medical University, Moscow, Russia; 2FLENI Institute, Buenos Aires, Argentina; 3Department of Neurology, University Hospital of Rennes, France; 4University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada; 5Queen Mary University of London, London, United Kingdom; 6Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain; 7St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada; 8Department of Neurology, Multiple Sclerosis Center, University of Miami, Miami, FL; 9Jefferson University Hospital, Philadelphia, PA; 10Rush Medical College, Chicago, IL; 11Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon; 12Merck KGaA, Darmstadt, Germany; 13EMD Serono Research & Development Institute Inc, Billerica, MA

VIEW THE ABSTRACT
ID: DXT43
Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the EXPAND Study
Le H. Hua,1 Amit Bar-Or,2 Fred D. Lublin,3 Xiangyi Meng,4 Wendy Su,4 Bruce A.C. Cree,5 Robert J. Fox6
1Lou Ruvo Center for Brain Health, Las Vegas, NV; 2Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 3Icahn School of Medicine at Mount Sinai, New York, NY; 4Novartis Pharmaceuticals Corporation, East Hanover, NJ; 5Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA; 6Cleveland Clinic, Cleveland, OH
VIEW THE ABSTRACT